Study Suggests Benefits For Oral Cannabidiol in Hospitalized Patients With COVID-19

In an interview with Pharmacy Times®, Guillermo Torre-Amione, MD, PhD, FACC, the chairman of Cardiol Therapeutics, discusses the potential use for CBD in hospitalized patients with COVID-19, as well as its therapeutic benefits in certain patients with cardiovascular disease.

Pharmacy Times interviewed Guillermo Torre-Amione, MD, PhD, FACC, the chairman of Cardiol Therapeutics, on a phase 2/3 outcomes study assessing oral cannabidiol (CBD) in hospitalized patients testing positive for COVID-19.

In this discussion, Torre-Amione explains the potential benefits for anti-inflammatory therapies for these patients, as well as how CBD specifically can be applied. He also describes a use for CBD in treating cardiovascular disease related to viral damage, and what other anti-inflammatory therapies may soon be available.

Related Content:

RetailHospitalInterviews
Ribociclib Offers Improved Overall Survival in Postmenopausal Patients with HR-Positive, HER2-Negative Advanced Breast Cancer
Study: Interprofessional Collaboration Reduces Incidence of Hospital-Onset C. Difficile
Study: Half of Patients Hospitalized With COVID-19 Have at Least 1 Symptom 2 Years Later